Last reviewed · How we verify
Tegoprazan/Amoxicillin/Clarithromycin
This triple-therapy combination uses tegoprazan to reduce gastric acid while amoxicillin and clarithromycin work synergistically as antibiotics to eradicate Helicobacter pylori infection.
This triple-therapy combination uses tegoprazan to reduce gastric acid while amoxicillin and clarithromycin work synergistically as antibiotics to eradicate Helicobacter pylori infection. Used for Helicobacter pylori eradication in patients with peptic ulcer disease or gastritis.
At a glance
| Generic name | Tegoprazan/Amoxicillin/Clarithromycin |
|---|---|
| Also known as | Tegoprazan triple therapy (TAC) |
| Sponsor | HK inno.N Corporation |
| Drug class | Proton pump inhibitor (tegoprazan) + antibiotic combination (amoxicillin/clarithromycin) |
| Target | H+/K+-ATPase (tegoprazan); bacterial cell wall and protein synthesis (amoxicillin/clarithromycin) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Tegoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits the proton pump to suppress gastric acid secretion, creating an optimal environment for antibiotic efficacy. Amoxicillin and clarithromycin are bactericidal and bacteriostatic antibiotics, respectively, that target H. pylori through different mechanisms. Together, this triple regimen aims to achieve high eradication rates of H. pylori, which causes peptic ulcer disease and gastritis.
Approved indications
- Helicobacter pylori eradication in patients with peptic ulcer disease or gastritis
Common side effects
- Diarrhea
- Nausea
- Abdominal discomfort
- Taste disturbance
- Headache
Key clinical trials
- Fecal Molecular Susceptibility-guided Hp First-line Therapy (PHASE4)
- Fecal Molecular Susceptibility-guided Hp Rescue Therapy (PHASE4)
- Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1) (PHASE4)
- Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment (PHASE4)
- Comparison of Twice- and Four-times-daily Amoxicillin Administration in 2-week Tegoprazan-based H. Pylori Eradication
- Tegoprazan- Versus PPI-based H. Pylori Eradication
- Tegoprazan-containing Sequential for H. Pylori (NA)
- Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Tegoprazan vs Esomeprazole (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tegoprazan/Amoxicillin/Clarithromycin CI brief — competitive landscape report
- Tegoprazan/Amoxicillin/Clarithromycin updates RSS · CI watch RSS
- HK inno.N Corporation portfolio CI